Publications

BibTex format

@article{Obon-Santacana:2015:10.1002/ijc.29853,
author = {Obon-Santacana, M and Freisling, H and Peeters, PH and Lujan-Barroso, L and Ferrari, P and Boutron-Ruault, M-C and Mesrine, S and Baglietto, L and Turzanski-Fortner, R and Katzke, VA and Boeing, H and Quiros, JR and Molina-Portillo, E and Larranaga, N and Chirlaque, M-D and Barricarte, A and Khaw, K-T and Wareham, N and Travis, RC and Merritt, MA and Gunter, MJ and Trichopoulou, A and Lagiou, P and Naska, A and Palli, D and Sieri, S and Tumino, R and Fiano, V and Galassom, R and Bueno-de-Mesquita, HBA and Onland-Moret, NC and Idahl, A and Lundin, E and Weiderpass, E and Vesper, H and Riboli, E and Duell, EJ},
doi = {10.1002/ijc.29853},
journal = {International Journal of Cancer},
pages = {1129--1138},
title = {Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort},
url = {http://dx.doi.org/10.1002/ijc.29853},
volume = {138},
year = {2015}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Acrylamide, classified in 1994 by IARC as “probably carcinogenic to humans,” was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA+HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95%CI: 0.49–1.48; HRHbGA;Q5vsQ1: 0.94, 95%CI: 0.54–1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI < 25 vs. ≥25 kg m−2, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
AU  - Obon-Santacana,M
AU  - Freisling,H
AU  - Peeters,PH
AU  - Lujan-Barroso,L
AU  - Ferrari,P
AU  - Boutron-Ruault,M-C
AU  - Mesrine,S
AU  - Baglietto,L
AU  - Turzanski-Fortner,R
AU  - Katzke,VA
AU  - Boeing,H
AU  - Quiros,JR
AU  - Molina-Portillo,E
AU  - Larranaga,N
AU  - Chirlaque,M-D
AU  - Barricarte,A
AU  - Khaw,K-T
AU  - Wareham,N
AU  - Travis,RC
AU  - Merritt,MA
AU  - Gunter,MJ
AU  - Trichopoulou,A
AU  - Lagiou,P
AU  - Naska,A
AU  - Palli,D
AU  - Sieri,S
AU  - Tumino,R
AU  - Fiano,V
AU  - Galassom,R
AU  - Bueno-de-Mesquita,HBA
AU  - Onland-Moret,NC
AU  - Idahl,A
AU  - Lundin,E
AU  - Weiderpass,E
AU  - Vesper,H
AU  - Riboli,E
AU  - Duell,EJ
DO  - 10.1002/ijc.29853
EP  - 1138
PY  - 2015///
SN  - 1097-0215
SP  - 1129
TI  - Acrylamide and glycidamide hemoglobin adduct levels and endometrial cancer risk: A nested case-control study in nonsmoking postmenopausal women from the EPIC cohort
T2  - International Journal of Cancer
UR  - http://dx.doi.org/10.1002/ijc.29853
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000369164700010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/42510
VL  - 138
ER  -

Download

ProfessorMarcGunter

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)